Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
Freedom Finance and Binance Join Forces in Digital Assets 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Warner Bros. Discovery Weighs Renewed Sale Talks With Paramount Skydance Amid Netflix Deal Review 
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Company announcement - No. 13/2018
Zealand announces net sales of Soliqua® 100/33 and Lyxumia®/Adlyxin® for the first quarter of 2018
- Net sales of Soliqua® 100/33 and Lyxumia®/Adlyxin® of EUR 14.5 million/USD 17.9 million in Q1 2018
- Zealand will receive royalties on global net sales
Copenhagen, April 27, 2018 - Zealand Pharma ("Zealand") announces Q1 2018 net sales by Sanofi from Soliqua® 100/33/ Suliqua® of EUR 9.0 million/USD 11.1 million and from Lyxumia®/Adlyxin® (lixisenatide) of EUR 5.5 million/USD 6.7 million.
The products are commercialized by Sanofi. Zealand receives 10% of global net sales and potentially up to USD 100 million in commercial milestones.
Zealand's first quarter results for 2018 will be published on May 16, 2018.
For further information, please contact:
Britt Meelby Jensen, CEO and President
Tel.: +45 51 67 61 28, e-mail: [email protected]
Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: [email protected]
About lixisenatide and Soliqua® 100/33
Lixisenatide is a Zealand-invented once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes. Zealand licensed the global development and commercialization rights to lixisenatide to Sanofi. Lixisenatide is marketed under the brand name Lyxumia® in more than 45 countries and under the brand name Adlyxin® in the U.S.
Sanofi has developed a fixed-dose combination of lixisenatide and insulin glargine 100 units/ml (Lantus®), which is sold under the brand name Soliqua® 100/33 in the United States and Suliqua® in Europe.
Soliqua® 100/33 is approved in the United States as an adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 units daily) or lixisenatide alone.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a late stage clinical portfolio of proprietary product candidates focusing on specialty gastrointestinal and metabolic diseases. In addition, it has two marketed products, commercialized by Sanofi, and two product candidates under license collaboration with Boehringer Ingelheim.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment
